ATE364396T1 - Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern - Google Patents

Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern

Info

Publication number
ATE364396T1
ATE364396T1 AT01911971T AT01911971T ATE364396T1 AT E364396 T1 ATE364396 T1 AT E364396T1 AT 01911971 T AT01911971 T AT 01911971T AT 01911971 T AT01911971 T AT 01911971T AT E364396 T1 ATE364396 T1 AT E364396T1
Authority
AT
Austria
Prior art keywords
treatment
polyenes
fungal infection
synthesis inhibitors
beta glucan
Prior art date
Application number
AT01911971T
Other languages
English (en)
Inventor
James Peter Burnie
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE364396T1 publication Critical patent/ATE364396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01911971T 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern ATE364396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections

Publications (1)

Publication Number Publication Date
ATE364396T1 true ATE364396T1 (de) 2007-07-15

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01911971T ATE364396T1 (de) 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern

Country Status (19)

Country Link
US (4) US20030180285A1 (de)
EP (4) EP1852128A1 (de)
JP (1) JP2003530357A (de)
CN (3) CN1420786A (de)
AT (1) ATE364396T1 (de)
AU (2) AU2001240890B2 (de)
BR (1) BR0109846A (de)
CA (1) CA2401836A1 (de)
CY (1) CY1106794T1 (de)
DE (1) DE60128893T2 (de)
DK (1) DK1267925T3 (de)
ES (1) ES2287105T3 (de)
GB (1) GB0008305D0 (de)
NO (1) NO20024815L (de)
NZ (1) NZ520899A (de)
PL (1) PL358394A1 (de)
PT (1) PT1267925E (de)
RU (1) RU2262952C2 (de)
WO (1) WO2001076627A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1457499A1 (de) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitoren des extrazellulären Hitzeschockproteins Hsp90
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
SG153877A1 (en) * 2004-07-02 2009-07-29 Neutec Pharma Plc Treatment of cancer
KR20070050918A (ko) 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
CN101193862B (zh) * 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) * 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
WO2026133151A1 (en) * 2024-12-16 2026-06-25 Universita' Degli Studi Di Roma "Tor Vergata" Pharmaceutical composition containing trifarotene for use in the treatment of fungal infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
NO20024815L (no) 2002-12-02
WO2001076627A8 (en) 2001-11-15
CY1106794T1 (el) 2012-05-23
EP1852128A1 (de) 2007-11-07
BR0109846A (pt) 2003-06-03
WO2001076627A1 (en) 2001-10-18
US20080193459A1 (en) 2008-08-14
EP1267925B8 (de) 2007-08-29
US20100285029A1 (en) 2010-11-11
RU2002129510A (ru) 2004-03-27
EP1267925A1 (de) 2003-01-02
DK1267925T3 (da) 2007-10-15
US20030180285A1 (en) 2003-09-25
ES2287105T3 (es) 2007-12-16
CN101683525A (zh) 2010-03-31
JP2003530357A (ja) 2003-10-14
EP1267925B1 (de) 2007-06-13
PL358394A1 (en) 2004-08-09
PT1267925E (pt) 2007-09-04
GB0008305D0 (en) 2000-05-24
DE60128893T2 (de) 2007-12-06
RU2262952C2 (ru) 2005-10-27
AU4089001A (en) 2001-10-23
CN101095952A (zh) 2008-01-02
EP1818062A1 (de) 2007-08-15
NO20024815D0 (no) 2002-10-04
US20080181884A1 (en) 2008-07-31
EP1818062A3 (de) 2007-10-24
EP2011512A1 (de) 2009-01-07
CN1420786A (zh) 2003-05-28
CA2401836A1 (en) 2001-10-18
AU2001240890B2 (en) 2005-06-16
DE60128893D1 (de) 2007-07-26
NZ520899A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
DE60128893D1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
EP1485130A4 (de) Reagenzien und behandlungsverfahren für autoimmunkrankheiten
MX421450B (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19)
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE279442T1 (de) Humanisierte antikörper, die amyloid beta peptid sequestrieren
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
BRPI0415230A (pt) anticorpo biespecìfico de substituição de proteìnas funcionais
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EA200600275A1 (ru) Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
BRPI0406574A (pt) Conjugados de anticorpo - antraciclina
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
ATE437186T1 (de) Anti-epcam-immunoglobuline
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DK1534750T3 (da) Terapeutisk brug af monoklonale antistoffer mod angiotensin-II type-1 receptoren
ATE411056T1 (de) Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1267925

Country of ref document: EP